Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions.

IF 3 4区 医学 Q3 Biochemistry, Genetics and Molecular Biology
Adriana C Rodriguez, Zannel Blanchard, Kathryn A Maurer, Jason Gertz
{"title":"Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions.","authors":"Adriana C Rodriguez,&nbsp;Zannel Blanchard,&nbsp;Kathryn A Maurer,&nbsp;Jason Gertz","doi":"10.1007/s12672-019-0358-9","DOIUrl":null,"url":null,"abstract":"<p><p>Endometrial cancer is the most common gynecological cancer in the developed world, and it is one of the few cancer types that is becoming more prevalent and leading to more deaths in the USA each year. The majority of endometrial tumors are considered to be hormonally driven, where estrogen signaling through estrogen receptor α (ER) acts as an oncogenic signal. The major risk factors and some treatment options for endometrial cancer patients emphasize a key role for estrogen signaling in the disease. Despite the strong connections between estrogen signaling and endometrial cancer, important molecular aspects of ER function remain poorly understood; however, progress is being made in our understanding of estrogen signaling in endometrial cancer. Here, we discuss the evidence for the importance of estrogen signaling in endometrial cancer, details of the endometrial cancer-specific actions of ER, and open questions surrounding estrogen signaling in endometrial cancer.</p>","PeriodicalId":13060,"journal":{"name":"Hormones & Cancer","volume":"10 2-3","pages":"51-63"},"PeriodicalIF":3.0000,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12672-019-0358-9","citationCount":"152","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormones & Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-019-0358-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 152

Abstract

Endometrial cancer is the most common gynecological cancer in the developed world, and it is one of the few cancer types that is becoming more prevalent and leading to more deaths in the USA each year. The majority of endometrial tumors are considered to be hormonally driven, where estrogen signaling through estrogen receptor α (ER) acts as an oncogenic signal. The major risk factors and some treatment options for endometrial cancer patients emphasize a key role for estrogen signaling in the disease. Despite the strong connections between estrogen signaling and endometrial cancer, important molecular aspects of ER function remain poorly understood; however, progress is being made in our understanding of estrogen signaling in endometrial cancer. Here, we discuss the evidence for the importance of estrogen signaling in endometrial cancer, details of the endometrial cancer-specific actions of ER, and open questions surrounding estrogen signaling in endometrial cancer.

Abstract Image

Abstract Image

雌激素信号在子宫内膜癌:一个关键的致癌途径与几个悬而未决的问题。
子宫内膜癌是发达国家最常见的妇科癌症,它是少数几种越来越普遍的癌症类型之一,每年在美国导致更多的死亡。大多数子宫内膜肿瘤被认为是激素驱动的,其中雌激素信号通过雌激素受体α (ER)作为致癌信号。子宫内膜癌患者的主要危险因素和一些治疗方案强调了雌激素信号在该疾病中的关键作用。尽管雌激素信号和子宫内膜癌之间有很强的联系,但雌激素受体功能的重要分子方面仍然知之甚少;然而,我们对子宫内膜癌中雌激素信号的理解正在取得进展。在这里,我们讨论了雌激素信号在子宫内膜癌中的重要性的证据,ER的子宫内膜癌特异性作用的细节,以及围绕雌激素信号在子宫内膜癌中的开放性问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Hormones & Cancer
Hormones & Cancer ONCOLOGY-ENDOCRINOLOGY & METABOLISM
CiteScore
4.60
自引率
0.00%
发文量
0
期刊介绍: Hormones and Cancer is a unique multidisciplinary translational journal featuring basic science, pre-clinical, epidemiological, and clinical research papers. It covers all aspects of the interface of Endocrinology and Oncology. Thus, the journal covers two main areas of research: Endocrine tumors (benign & malignant tumors of hormone secreting endocrine organs) and the effects of hormones on any type of tumor. We welcome all types of studies related to these fields, but our particular attention is on translational aspects of research. In addition to basic, pre-clinical, and epidemiological studies, we encourage submission of clinical studies including those that comprise small series of tumors in rare endocrine neoplasias and/or negative or confirmatory results provided that they significantly enhance our understanding of endocrine aspects of oncology. The journal does not publish case studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信